Common Contracts
5 similar Underwriting Agreement contracts by Venator Materials PLC, Gensight Biologics S.A., OM Asset Management PLC, Orphazyme a/S
ORPHAZYME A/S (a Danish public limited liability company) [•] Ordinary Shares (nominal value DKK 1 per share) and [•] American Depositary Shares each Representing One Ordinary Share UNDERWRITING AGREEMENTUnderwriting Agreement • September 21st, 2020 • Orphazyme a/S • Pharmaceutical preparations • New York
The Underlying Shares will, following subscription by the Underwriters, be deposited pursuant to the terms of a deposit agreement (the “Deposit Agreement”), to be dated as of [•], 2020, by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and holders and beneficial holders from time to time of the ADSs. Upon deposit of any Ordinary Shares, the Depositary will issue ADSs representing the Ordinary Shares so deposited, which ADSs may be evidenced by American Depositary Receipts (“ADRs”) registered in book-entry form on the Direct Registration System (“DRS”) administered by the Depository Trust Company (“DTC”). Unless the context otherwise requires, references to the “Initial ADSs,” the “Option ADSs” and the “Securities” shall be deemed to include the ADRs evidencing the same and the Underlying Shares represented thereby.
VENATOR MATERIALS PLC (a public limited company incorporated under the laws of England and Wales) 22,700,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • August 7th, 2017 • Venator Materials PLC • Industrial organic chemicals • New York
The undersigned, a shareholder, officer and/or director of Venator Materials PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), understands that Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC (together, the “Representatives”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company, Huntsman International LLC (“HI”), a Delaware limited liability company, and Huntsman (Holdings) Netherlands B.V., a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands (together with HI, the “Selling Shareholders”), providing for the offer and sale by the Selling Shareholders (the “Offering”) of the Company’s ordinary shares, par value $0.32 per share (“Ordinary Shares”). For good and valuable consideration, the receipt and sufficiency of which are her
UNDERWRITING AGREEMENTUnderwriting Agreement • July 14th, 2017 • Venator Materials PLC • Industrial organic chemicals • New York
Citigroup Global Markets Inc. Goldman Sachs & Co. LLC Merrill Lynch, Pierce, Fenner & Smith Incorporated J.P. Morgan Securities LLC
GENSIGHT BIOLOGICS S.A. (a société anonyme incorporated under the laws of France) [●] American Depositary Shares, Each Representing [●] Ordinary Share[s] (nominal value €[●] per share) UNDERWRITING AGREEMENTUnderwriting Agreement • October 6th, 2015 • Gensight Biologics S.A. • Biological products, (no disgnostic substances) • New York
OM Asset Management plc (a public limited company formed under the laws of England and Wales) [ ] Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2015 • OM Asset Management PLC • Investment advice • New York
The undersigned, a shareholder [and an officer and/or director](2) of OM Asset Management plc, a public limited company formed under the laws of England and Wales (the “Company”), understands that Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Morgan Stanley & Co. LLC (“Morgan Stanley”), Citigroup Global Markets Inc. and Credit Suisse Securities (USA) LLC propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company and the Selling Shareholder providing for the public offering (the “Offering”) of the Company’s ordinary shares, nominal value $0.001 per share (the “Ordinary Shares”). In recognition of the benefit that the Offering will confer upon the undersigned as a shareholder [and an officer and/or director] of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each underwriter to be named in the Underwriting Agreement that, [duri
